Enhancing the immune response against recurrent ovarian cancer
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
This study is looking at how to boost the immune system's fight against recurrent ovarian cancer by using a special treatment called APL-2, and it's for patients who are dealing with this type of cancer and its related complications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10892999 on NIH RePORTER |
What this research studies
This research focuses on improving the immune system's ability to fight recurrent epithelial ovarian cancer by targeting specific components of the immune response. The study aims to understand how certain immune cells, particularly neutrophils, can suppress the body's natural defenses against tumors and how this suppression can be overcome. By using a peptide inhibitor called APL-2, the researchers will conduct a clinical trial to evaluate its effectiveness in enhancing anti-tumor immunity in patients with recurrent ovarian cancer and associated malignant effusions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent epithelial ovarian cancer who are experiencing persistent malignant effusions.
Not a fit: Patients with early-stage ovarian cancer or those who do not have recurrent disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with recurrent ovarian cancer.
How similar studies have performed: Previous research has shown promise in targeting immune suppression in tumors, suggesting that this approach could be effective, although the specific use of APL-2 in this context is novel.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Zsiros, Emese — Roswell Park Cancer Institute Corp
- Study coordinator: Zsiros, Emese
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.